Leukemia Therapeutics
1. Arranon patent expiration
Treatment: Treatment of patients with t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens; Treatment of patients with t-ce...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5747472 | SANDOZ | Therapeutic methods for using ARA-G derivatives |
Feb, 2013
(12 years ago) | |
| US5424295 | SANDOZ | 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
Jun, 2017
(8 years ago) | |
| US5492897 | SANDOZ | Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
Feb, 2013
(12 years ago) | |
| US5821236 | SANDOZ | Tumor treatment with arabinofuranosyl purine derivatives |
Feb, 2013
(12 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 28, 2012 |
Drugs and Companies using NELARABINE ingredient
Market Authorisation Date: 28 October, 2005
Dosage: INJECTABLE
More Information on Dosage
ARRANON family patents
2. Brukinsa patent expiration
Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl), in combination with obinutuzumab, after two or more lines of systemic therapy; Treatment of adult patients with relaps...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11851437 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10927117 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11701357 | BEONE MEDICINES USA | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(13 years from now) | |
| US11884674 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11911386 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11591340 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10570139 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11896596 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11786531 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11970500 | BEONE MEDICINES USA | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11142528 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US12233069 | BEONE MEDICINES USA | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| ODE*(ODE*) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Dosage: CAPSULE; TABLET
More Information on Dosage
BRUKINSA family patents
3. Calquence patent
expiration
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated mantle cell lymphoma wh...
CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(10 months from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(10 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(6 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(10 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Dosage: CAPSULE
How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage
CALQUENCE family patents
4. Calquence patent expiration
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic Read More
CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(10 years from now) | |
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(10 months from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(6 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Dosage: TABLET
More Information on Dosage
CALQUENCE family patents
5. Clolar patent expiration
Treatment: Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661136 | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan, 2018
(7 years ago) | |
|
US5661136 (Pediatric) | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 28, 2011 |
| Pediatric Exclusivity(PED) | Jun 28, 2012 |
Drugs and Companies using CLOFARABINE ingredient
Market Authorisation Date: 28 December, 2004
Dosage: SOLUTION
How can I launch a generic of CLOLAR before it's drug patent expiration?
More Information on Dosage
CLOLAR family patents
6. Daurismo patent expiration
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >=...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(5 years from now) | |
| US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| US11891372 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
| Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Dosage: TABLET
More Information on Dosage
DAURISMO family patents
7. Gleevec patent expiration
Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)
GLEEVEC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5521184 (Pediatric) | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jul, 2015
(10 years ago) | |
| US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(6 years ago) | |
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(11 years ago) | |
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
| US6958335 | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Dec, 2021
(4 years ago) | |
| US7544799 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
|
US7544799 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
USRE43932 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
US6894051 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov, 2019
(6 years ago) | |
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-583) | Dec 19, 2011 |
| Orphan Drug Exclusivity(ODE) | Jan 25, 2020 |
| New Indication(I-666) | Jan 25, 2016 |
| Orphan Drug Exclusivity(ODE-40) | Jan 25, 2020 |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Dosage: CAPSULE; TABLET
How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage
GLEEVEC family patents
8. Grafapex patent expiration
Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7199162 | MEDEXUS | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
Mar, 2026
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2030 |
| Orphan Drug Exclusivity(ODE-513) | Jan 21, 2032 |
| Orphan Drug Exclusivity(ODE-514) | Jan 21, 2032 |
Drugs and Companies using TREOSULFAN ingredient
NCE-1 date: 21 January, 2029
Market Authorisation Date: 21 January, 2025
Dosage: POWDER
More Information on Dosage
GRAFAPEX family patents
9. Iclusig patent expiration
Treatment: A method for treating acute lymphoblastic leukemia; A method for treating chronic myeloid Read More
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(1 year, 14 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029533 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
Dec, 2026
(11 months from now) | |
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
| New Indication(I-849) | Dec 18, 2023 |
| New Indication(I-934) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-472) | Mar 19, 2031 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Dosage: TABLET
How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage
ICLUSIG family patents
10. Idhifa patent expiration
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
IDHIFA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(6 years from now) | |
| US10093654 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| US9732062 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Sep, 2034
(8 years from now) | |
| US9738625 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(6 years from now) | |
| US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Dosage: TABLET
More Information on Dosage
IDHIFA family patents
11. Imbruvica patent expiration
Treatment: Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatme...
IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(7 years from now) | |
| US9181257 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8957079 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8735403 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US7514444 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US8008309 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(1 year, 10 months from now) | |
| US8697711 | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8563563 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(1 year, 9 months from now) | |
| US9814721 | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US10653696 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US8999999 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
| US10004746 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10016435 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9801881 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US9801883 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9125889 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8476284 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10463668 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US10695350 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US8563563 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(1 year, 3 months from now) | |
| US8703780 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8952015 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8497277 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10478439 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10751342 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(7 years from now) | |
| US8754091 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10010507 | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10213386 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9655857 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10828259 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US12364698 | PHARMACYCLICS LLC | NA |
Apr, 2036
(10 years from now) | |
| US12201690 | PHARMACYCLICS LLC | Formulations/compositions comprising ibrutinib |
Jun, 2039
(13 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(2 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(8 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(8 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Dosage: TABLET; CAPSULE; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
12. Revuforj patent expiration
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric pati...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10683302 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11479557 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-504) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-505) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
13. Rezlidhia patent expiration
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a can...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US12275715 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US12053463 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(13 years from now) | |
| US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(13 years from now) | |
| US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(13 years from now) | |
| US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(13 years from now) | |
| US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Dosage: CAPSULE
More Information on Dosage
REZLIDHIA family patents
14. Rydapt patent expiration
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard c...
RYDAPT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(3 years ago) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(4 years from now) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Dosage: CAPSULE
How can I launch a generic of RYDAPT before it's drug patent expiration?
More Information on Dosage
RYDAPT family patents
15. Scemblix patent expiration
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
Oct, 2035
(9 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12252479 | NOVARTIS | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| US12252478 | NOVARTIS | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| New Indication(I-953) | Oct 29, 2027 |
| New Indication(I-954) | Oct 29, 2027 |
| ODE*(ODE*) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-499) | Oct 29, 2031 |
| Orphan Drug Exclusivity(ODE-500) | Oct 29, 2031 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Dosage: TABLET
More Information on Dosage
SCEMBLIX family patents
16. Sprycel patent expiration
Treatment: A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia; A method for the treatment of cancer
SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125875 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(5 years ago) | |
|
US7153856 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(5 years ago) | |
|
US6596746 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Dec, 2020
(5 years ago) | |
| US7125875 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(5 years ago) | |
| US6596746 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Jun, 2020
(5 years ago) | |
| US7153856 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(5 years ago) | |
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(11 months ago) | |
|
US7491725 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(8 months from now) | |
|
US8680103 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-120) | May 21, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 28, 2013 |
| M(M-94) | Oct 28, 2013 |
| New Patient Population(NPP) | Nov 09, 2020 |
| New Indication(I-791) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-164) | Nov 09, 2024 |
| Orphan Drug Exclusivity(ODE-225) | Dec 21, 2025 |
| Pediatric Exclusivity(PED) | Jun 21, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Dosage: TABLET
How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage
SPRYCEL family patents
17. Synribo patent expiration
Treatment: Treatment of patients with leukemia including chronic myeloid/myelogenous leukemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45128 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842687 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(6 years ago) | |
| US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
| Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
| Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Dosage: POWDER
How can I launch a generic of SYNRIBO before it's drug patent expiration?
More Information on Dosage
SYNRIBO family patents
18. Tibsovo patent expiration
Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes; A method for treating newly diagnosed aml with ivosidenib and az...
TIBSOVO IPR and PTAB Proceedings
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(7 years from now) | |
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(10 years from now) | |
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(13 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-816) | May 02, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-893) | May 25, 2025 |
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Dosage: TABLET
How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage
TIBSOVO family patents
19. Treanda patent expiration
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients wi...
TREANDA's oppositions filed in EPO
TREANDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(3 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(4 years from now) | |
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(5 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(4 years from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
| Pediatric Exclusivity(PED) | May 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Dosage: POWDER; SOLUTION
How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage
TREANDA family patents
20. Trisenox patent expiration
Treatment: In combination with tretinoin, treating adults and pediatric patients 1 year and older with newly-diagnosed low-risk acute promyelocytic leukemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6982096 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US8273379 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6855339 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6884439 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6723351 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6861076 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-167) | Jan 12, 2025 |
Drugs and Companies using ARSENIC TRIOXIDE ingredient
Market Authorisation Date: 25 September, 2000
Dosage: INJECTABLE
How can I launch a generic of TRISENOX before it's drug patent expiration?
More Information on Dosage
TRISENOX family patents
21. Vanflyta patent expiration
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(1 year, 2 months from now) | |
| US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(1 year, 2 months from now) | |
| US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(4 years from now) | |
| US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(4 years from now) | |
| US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(5 years from now) | |
| US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(1 year, 2 months from now) | |
| US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(3 years from now) | |
| US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(3 years from now) | |
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(7 years from now) | |
| US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
22. Venclexta patent expiration
Treatment: Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have re...
VENCLEXTA's oppositions filed in EPO
VENCLEXTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(5 years from now) | |
| US10730873 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(5 years from now) | |
| US8722657 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(4 years from now) | |
| US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11369599 | ABBVIE | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Dosage: TABLET
How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage
VENCLEXTA family patents
23. Xospata patent expiration
Treatment: Treatment of acute myeloid leukemia (aml)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Nov, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(4 years from now) | |
| US11938133 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11944620 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938130 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938131 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938132 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Dosage: TABLET
How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage
XOSPATA family patents
24. Zydelig patent expiration
Treatment: For the treatment of patients with cll, fl, or sll; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic ...
ZYDELIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6800620 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8637533 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8492389 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8138195 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US6949535 | GILEAD SCIENCES INC | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(5 months ago) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(4 years from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Dosage: TABLET
How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage
ZYDELIG family patents